JAK/STAT Signaling - Cancer
Various ligands including cytokines (e.g. interferons and interleukins), hormones (e.g. erythropoietin and growth hormone) and their cell surface receptors activate JAK proteins, which autophosphorylate, and then phosphorylate the receptor. Subsequently, JAKs phosphorylate a specific tyrosine residue on the STAT protein, promoting dimerization via SH2 domains. The activated STATs form homo-/heterodimers and translocate to the nucleus to trigger target gene transcription. In addition, suppressors of cytokine signaling (SOCS) family inhibit receptor signaling via homologous or heterologous feedback regulation. Dysregulation in JAK/STAT signaling is associated with diseases such as atherosclerosis, immunodeficiencies and cancer.
Shop By
- B5836 AZ5104Target: EGFRSummary: EGFR inhibitor
- B4970 HO-38671 CitationTarget: STATSummary: STAT3 inhibitor, selective
- B2283 NiclosamideTarget: STATSummary: Inhibitor of the STAT3 signaling pathway
- B1104 AZD-92911 CitationTarget: EGFRSummary: Mutated forms EGFR inhibitor
- A8375 AZD8931 (Sapitinib)Target: EGFR|ErbBSummary: ErbB inhibitor
- A8366 ARRY-380Target: HER2Summary: Tyrosine kinase HER2 and p95-HER2 inhibitor
- A8357 AG-1478Target: EGFRSummary: EGFR inhibitor,potent and selective
- A8338 NSC 748595 CitationTarget: STATSummary: Stat3 inhibitor
- A8319 Dacomitinib (PF299804, PF299)Target: ErbBSummary: HER inhibitor
- A2224 Stattic5 CitationTarget: STATSummary: STAT3 inhibitor,small-molecule and potent